• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avista Healthcare Partners Announces Promotions

    1/5/26 8:00:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email

    NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced three key promotions within its investment team, reflecting the firm's continued growth and commitment to developing top talent.

    • Ryan Moran has been promoted to Partner;
    • Garrett Lustig has been promoted to Partner; and
    • Elaine Tang has been promoted to Principal.

    David Burgstahler, Managing Partner and Chief Executive Officer of Avista, commented:

    "We are thrilled to recognize Ryan, Garrett, and Elaine for their outstanding contributions to Avista's success as well as their partnerships with our portfolio company management teams and Boards. The firm's growth and continued development of our team underscore the depth and strength of the firm's leadership team. We look forward to their leadership as we pursue new and compelling investment opportunities in the healthcare sector."

    Ryan Moran: Ryan joined Avista in 2018. Prior to joining Avista, he was an Associate at Morgan Stanley Capital Partners where he focused on private equity investments across a range of industries. Prior to joining Morgan Stanley, he worked as an Analyst in the investment banking division at Bank of America Merrill Lynch. Ryan received a B.A. from The George Washington University and an M.B.A. from Harvard Business School. He currently serves as a Director of Cosette Pharmaceuticals, GCM Holding Corporation, WellSpring Consumer Healthcare, and XIFIN.

    Garrett Lustig: Garrett joined Avista in 2015. Prior to joining Avista, he worked in investment banking at Centerview Partners. Garrett received a B.S. from Duke University. He currently serves as a Director of ACP Northern Holdings, EBi Bone Healing, eMolecules, Organogenesis (NASDAQ:ORGO), Taconic Biosciences, and Terrats Medical and previously served as a Director of Solmetex, Spear Education, United BioSource Corporation, and XIFIN.

    Elaine Tang: Elaine joined Avista in 2022. Prior to joining Avista, she worked in private equity at Partners Group. Elaine received a B.A. from Wellesley College and an M.B.A. from Harvard Business School. She currently serves as a Director of PK Benelux and Probo Medical.

    About Avista Healthcare Partners

    Avista Healthcare Partners, founded in 2005 by Thompson Dean and David Burgstahler, is a leading New York-based private equity firm with over $10 billion invested in more than 50 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows and robust growth prospects – targeting healthcare product and technology businesses with clear scale potential across four sub-sectors experiencing strong tailwinds. The team is supported by a group of seasoned Strategic Executives enhancing the entire investment process through strategic insight, long-term value and sustainable businesses. For more information, visit www.avistahealthcare.com or follow Avista on LinkedIn.

    For media inquiries, please contact:

    Daniel Yunger / James Lindsay

    Kekst CNC

    [email protected] / [email protected]

    917.574.8582 / 917.842.4119

    Cision View original content:https://www.prnewswire.com/news-releases/avista-healthcare-partners-announces-promotions-302652569.html

    SOURCE Avista Healthcare Partners

    Get the next $ORGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avista Healthcare Partners Announces Promotions

    NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced three key promotions within its investment team, reflecting the firm's continued growth and commitment to developing top talent. Ryan Moran has been promoted to Partner;Garrett Lustig has been promoted to Partner; andElaine Tang has been promoted to Principal.David Burgstahler, Managing Partner and Chief Executive Officer of Avista, commented:"We are thrilled to recognize Ryan, Garrett, and Elaine for their outstanding contributions to Avista's success as well as their partnerships with our portfolio company management teams and Board

    1/5/26 8:00:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Announces Initiation of Biologics License Application for ReNu®

    CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for ReNu,® a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis. Organogenesis plans to complete the BLA submission with the final modules submitted in the first half of 2026. "This is another significant achievement for

    12/23/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

    Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administration (FDA) resulting in confirmation to initiate a rolling Biologics Licenses Application (BLA) for ReNu planned before the end of December. "We are excited about the outcome of our FDA meeting and reaching thi

    12/15/25 4:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    SEC Filings

    View All

    SEC Form 8-K filed by Organogenesis Holdings Inc.

    8-K - Organogenesis Holdings Inc. (0001661181) (Filer)

    12/29/25 4:31:02 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Organogenesis Holdings Inc.

    144 - Organogenesis Holdings Inc. (0001661181) (Subject)

    12/16/25 4:32:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Organogenesis Holdings Inc.

    144 - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/25/25 4:56:17 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nussdorf Glenn H sold $1,027,060 worth of shares (200,000 units at $5.14), decreasing direct ownership by 7% to 2,565,591 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    12/18/25 4:19:19 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H sold $1,592,120 worth of shares (300,000 units at $5.31), decreasing direct ownership by 10% to 2,765,591 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/26/25 6:24:24 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Organogenesis with a new price target

    Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

    6/28/24 8:20:16 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

    Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

    2/7/24 6:56:39 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Organogenesis with a new price target

    Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00

    6/15/23 7:30:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Leadership Updates

    Live Leadership Updates

    View All

    Organogenesis Expands Manufacturing Capacity to Support Future Growth

    CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

    11/22/24 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

    CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

    11/12/24 4:01:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    7/3/23 6:00:00 AM ET
    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

    CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Summary: Net product revenue of $150.5 million for the third quarter of 2025, an increase of $35.3 million compared to net product revenue of $115.2 million for the third quarter of 2024. Net product revenue for the third quarter of 2025 consists of: Net product revenue from Advanced Wound Car

    11/6/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

    CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. Eastern Time on November 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access

    10/1/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

    SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 3:35:42 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care